503039-05-2Relevant articles and documents
Substituted N-(2-aminophenyl)-benzamides, (E)-N-(2-aminophenyl)-acrylamides and their analogues: Novel classes of histone deacetylase inhibitors
Moradei, Oscar,Leit, Silvana,Zhou, Nancy,Frechette, Sylvie,Paquin, Isabelle,Raeppel, Stephane,Gaudette, Frederic,Bouchain, Giliane,Woo, Soon H.,Vaisburg, Arkadii,Fournel, Marielle,Kalita, Ann,Lu, Aihua,Trachy-Bourget, Marie-Claude,Yan, Pu T.,Liu, Jianhong,Li, Zuomei,Rahil, Jubrail,MacLeod, A. Robert,Besterman, Jeffrey M.,Delorme, Daniel
, p. 4048 - 4052 (2007/10/03)
Inhibition of histone deacetylases (HDACs) is emerging as a new strategy in human cancer therapy. Novel 2-aminophenyl benzamides and acrylamides, that can inhibit human HDAC enzymes and induce hyperacetylation of histones in human cancer cells, have been
Inhibitors of histone deacetylase
-
, (2008/06/13)
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
Inhibitors of histone deacetylase
-
, (2008/06/13)
The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.